About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT01031680

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

This study is carried out to assess whether dapagliflozin lowers blood glucose, body weight and blood pressure, when added to patients existing medications and how it compares with their usual treatme...

Lead sponsor: AstraZeneca•60 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

AstraZeneca

Collaborators

Bristol-Myers Squibb

Age

45 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Type 2 diabetes mellitus.
•Cardiovascular disease
•Hypertension

Exclusion Criteria

•Patients with type 1 diabetes or diabetes insipidus
•Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes
•Any clinically significant illness, which would compromise the patient's safety and their participation in the study

Related studies

Health Ahead Comparative Effectiveness Study

NCT07669168 · Health Services Accessibility, Rural Health, and more

RECRUITINGPhase 3

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

NCT07136012 · Cardiovascular Disease

Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry

NCT07256249 · Cardiovascular Diseases

Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany

NCT06675552 · Heart Disease, Heart Failure, and more

RECRUITINGPhase 3

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

NCT07613294 · Atherosclerosis, Cardiovascular Diseases, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 29, 2013Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment922

Start dateFeb 2010

Last updatedOct 29, 2013

Condition

Type 2 Diabetes Mellitus Cardiovascular Disease Hypertension Inadequate Glycaemic Control

Locations shown

Research Site

Gulf Shores, Alabama

Research Site

Phoenix, Arizona

Research Site

Burbank, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 29, 2013Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions